© Reuters. FILE PHOTO: Illumina’s international headquarters is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photograph
By Blake Brittain
(Reuters) – Gene-sequencing big Illumina Inc (NASDAQ:) has settled a patent lawsuit introduced by Maryland biotech firm Ravgen Inc, which accused Illumina’s genetic exams of infringing its patents.
The businesses instructed a Delaware federal court docket Friday that they settled the case. Ravgen lawyer John Desmarais on Monday referred to as it “a mutually passable settlement between the 2 events” however didn’t disclose phrases of the deal, that are confidential.
San Diego-based Illumina declined to touch upon Monday.
Ravgen has filed a collection of lawsuits in opposition to firms together with Illumina, Natera (NASDAQ:) and Roche’s Ariosa Diagnostics over DNA-testing know-how. It gained a $272 million jury verdict in opposition to Labcorp in Texas final September and settled a lawsuit in opposition to Quest Diagnostics (NYSE:) shortly earlier than a trial was set to start in October.
Ravgen alleged in its 2020 criticism that Illumina’s Verifi and VeriSeq exams for fetal chromosome abnormalities and TruSight take a look at for most cancers markers infringe its patents. Ravgen’s patents relate to much less invasive diagnostic exams that analyze free-floating DNA from a affected person’s bloodstream, know-how the Columbia, Maryland-based firm stated it pioneered.
Illumina denied the allegations and argued the patents had been invalid.
A jury trial was scheduled to start subsequent October.
The case is Ravgen Inc v. Illumina Inc, U.S. District Court docket for the District of Delaware, No. 1:20-cv-01644.
